by admin | Oct 18, 2018 | Stem Cell Research, Stem Cell Therapy, Studies
A couple of weeks ago, scientists published findings showing that implanting human stem cells that are embedded within the engineered tissue can lead to the recovery of sensory perception in rats. The recovery of sensory perception is also accompanied by healing within the spinal cord and the ability to walk independently. The stem cells used in this experiment were collected from the membrane lining the mouth.
These results help demonstrate the potential for stem cells to help with spinal cord injuries but also point to the utility of combining stem cells with other factors to enhance their therapeutic effects. In this case, the researchers used a 3-dimensional scaffold to enable stem cells to attach and to stabilize them in the spinal cord. By adding growth factors, such as human thrombin and fibrinogen to the engineered tissue scaffolding, the researchers also increased the chances that attached stem cells would grow and differentiate.
The researchers compared the effects of their stem cell implants in paraplegic rats with the effects of adding no stem cells. Whereas the control rats who did not receive stem cells did not experience any improvement in mobility or sensation, 42% of the rats that did receive stem cells became better at supporting their weight on their hind limbs and at walking.
While these results are pre-clinical and do not apply directly to humans, the researchers conclude that further research is warranted. Given the positive impact of stem cells on the spinal cord in animals, it is reasonable to assume that stem cells may also benefit the human spinal cord. Further research will help clarify whether these stem cells can be adequately used to help treat patients with paraplegia.
by admin | Sep 17, 2018 | Alzheimer’s Disease, Health Awareness, Studies
For years, medical experts have warned of the medical concerns associated with opioids, including depression, weakened immune system, and digestive issues. Now, however, new research shows that they could be particularly dangerous for dementia patients.
The Dangers of Painkillers for Dementia Patients
According to research presented at the Alzheimer’s Association International Conference, opioid-based painkillers can triple the side effects of dementia. Individuals taking the drugs experienced more pronounced personality changes, significant increases in confusion and sedation, and lower activity levels throughout the day.
In another study, researchers focused exclusively on known as “Z drugs,” which are currently given to hundreds of thousands of patients with dementia to promote sleep. Drugs under this category included zolpidem, zopiclone, and zaleplon. Findings revealed that patients on these drugs faced an increased risk of bone fracture, which contributes to an increased risk of death in people with dementia.
A Widespread Problem
Alzheimer’s, which is the most common form of dementia, currently affects an estimated 5.7 million Americans. Roughly half of the people living in care homes and suffering from this or another form of dementia experience pain to some degree, which can result from unrelated medical conditions such as arthritis. Unfortunately, as dementia patients face compounding communication challenges, treating their pain can become more difficult.
The study has prompted experts to explore other, non-pharmaceutical means of treating pain and sleep disorders in dementia patients. Alzheimer’s research group leaders believe that the solution lies in finding nondrug interventions to help manage pain and promote quality of life while minimizing serious side effects like those revealed by the study findings. Regenerative therapy may be an option to consider for those battling Alzheimer’s disease or dementia.
by admin | Sep 13, 2018 | Stem Cell Research, Stem Cell Therapy, Studies
Patients usually recover from bone fractures with the right treatment, but sometimes the bone fails to heal because new tissue does not form and connect the broken pieces properly. Delayed union refers to cases where the bone takes longer than usual to heal, and nonunion refers to cases where the bone does not heal. In approximately 5 to 10 percent of cases of a fractured bone, delayed union or nonunion occurs. These conditions are associated with long-term pain and discomfort, and though can be addressed through surgical treatments, these interventions do not always lead to long-term healing.
In recent years, researchers have begun exploring the potential for mesenchymal stem cells to help address these important challenges of delayed union and nonunion. A review of the potential for these stem cells to help in these cases where fractures do not properly heal was recently published in the Journal of Biomedical Materials Research.
Mesenchymal stem cells are helpful in bone healing because they differentiate well and can differentiate into different cell lineages that are all important for bone formation, growth, and maintenance. These cell types include chondrocytes, osteoblasts, myoblasts, and adipocytes.
According to the authors of the review, mesenchymal stem cells can be used in conjunction with extracellular matrix scaffolds and biological adjuvants that promote growth, differentiation, and blood vessel formation, to help in the bone healing process when the delayed union or nonunion occurs. Future research will help to determine the best ways that mesenchymal stem cells can be used in combination with bioengineering strategies to help patients whose bone fractures do not heal or do not heal properly.
by admin | Sep 5, 2018 | Hyperbaric Oxygen Therapy, Stem Cell Research, Stem Cell Therapy, Studies, Traumatic Brain Injury
Traumatic brain injury (TBI) is one of the most common causes of disability in the United States, affecting over 13 million citizens. Traumatic brain injury is responsible for over 2 million emergency department visits, over a quarter of 1 million hospitalizations, and nearly 60,000 deaths each year.
Traumatic brain injury harms brain tissue in two phases. The first phase of injury occurs at the time of the traumatic incident. This initial injury may cause small or large areas of the brain to bleed. It may also shear (stretch/tear) nerve cells, making them dysfunctional. The second phase occurs hours or days after the initial injury. The brain is subjected to ongoing damage because of inflammation, cell death, and injury to blood vessels. Many people with TBI are left with lifelong problems with thinking, memory, and behavior.
In both of these phases of injury, one major way to help prevent long-term brain damage is by maintaining adequate blood flow to brain tissue. Unfortunately, once the damage has occurred, it can be a challenge to reverse the damage. Patients usually must endure months or years of physical and occupational therapy to regain what was lost. Moreover, patients often need substantial amounts of psychiatric and psychological support to treat mental health problems.
Fortunately, researchers are using hyperbaric oxygen therapy (HBOT) to improve blood flow to the brain in patients with traumatic brain injury. Hyperbaric oxygen therapy provides patients with pure oxygen (100%) at slightly higher pressures than they would experience normally. It is been used for hundreds of years to treat scuba divers who suffered “the bends” or decompression sickness; however, researchers are finding that hyperbaric oxygen therapy is a “coveted neurotherapeutic method for brain repair.”
To study the effects of hyperbaric oxygen therapy, researchers selected 10 people who had suffered mild traumatic brain injury in the previous 7 to 13 years. Patients all had brain damage that interfered with attention, memory, and thinking abilities.
Even though patients had sustained traumatic brain injury and brain damage a decade earlier, hyperbaric oxygen therapy was able to improve blood flow in the brain. Likewise, the amount of blood detected within the brain significantly increased, suggesting that hyperbaric oxygen therapy actually caused blood vessels in the brain to grow and multiply. Just as impressively, patients with chronic brain damage performed better on tests of cognition (i.e. thinking). They were able to process information more quickly, they had better motor function, and they were able to take in and process information about the world around them more efficiently.
Because people with traumatic brain damage have limited treatment options to improve their situations, these results are incredibly exciting. This was a study on 10 patients and more studies on larger numbers are still needed to build on these findings. Nonetheless, these results are quite encouraging for people with traumatic brain injury and their loved ones.
by admin | Aug 31, 2018 | Stem Cell Research, Stem Cell Therapy, Studies
Crohn’s disease is a chronic inflammatory bowel disease that has no cure. It causes abdominal pain, frequent diarrhea, weight loss, fatigue, and anemia. While the disease can be controlled to some degree through oral and injectable medications, life-threatening complications may occur.
One of the feared complications of Crohn’s disease is called a bowel fistula. A fistula is an abnormal connection between two places on the body. In Crohn’s disease, a fistula forms between the intestine and some other structure—the intestine essentially forms a “tunnel.” The fistula can form between one loop of intestine and another, between intestine and bladder, or even between the intestine and the outside of the body. This complication of Crohn’s disease is obviously quite distressing to patients.
Some bowel fistulas may close on their own with conservative treatments, but fistulas associated with Crohn’s disease do not respond well to available medical treatments. Those looking for an alternative treatment may be able to consider stem cell therapy.
Stem cells offer an interesting potential solution to this problem. Stem cells can provide a large dose of normal cells filled with molecules that can help direct normal bowel growth and development. Indeed, researchers have shown that autologous mesenchymal stem cells can help close and heal fistulas in patients with Crohn’s disease.
In phase I, II, and IIB clinical trials, stem cells derived from adipose tissue or bone marrow were directly infused into the bowel area (via a so-called intra-fistular injection). Across five clinical studies including over 100 patients, stem cell administration resulted in complete fistula healing in 50 to 80% of patients treated. Of those who did not obtain complete control fistula closure, almost all had evidence of improvement. These results support that autologous mesenchymal stem cell therapy is a promising future treatment for patients with Crohn’s disease and may offer patients enjoy a better quality of life.
by admin | Aug 8, 2018 | Stem Cell Research, Stem Cell Therapy, Studies
Ulcerative colitis and Crohn’s disease, together known as inflammatory bowel disease, are chronic disorders of the lower digestive tract that cause patients considerable difficulty and discomfort. Patients generally go through periods of normalcy punctuated by relapses. In cases of inflammatory bowel disease, patients may experience severe, and sometimes bloody diarrhea. Patients also experience crampy abdominal pain, the urgent need to defecate, pain with defecation and even fecal incontinence. Consequently, people with inflammatory disease often endure substantial amounts of suffering.
Inflammatory bowel disease is usually treated with 5-aminosalicylate or sulfasalazine. These drugs are intended to reduce inflammation in the bowels. Relapses do still occur for those patients taking these medicines. During these relapses, patients often need to take steroids for short or intermediate periods of time but over time, side effects can occur. Immunomodulators such as azathioprine, 6-mercaptopurine, and methotrexate can be used to reduce inflammation, however, these drugs can also cause side effects. Newer biologic response modifiers have helped people with severe inflammatory bowel disease but they may weaken the body’s immune system, making it more difficult to fight off infection. For these reasons, safer and more effective treatments for inflammatory bowel disease are needed.
Fortunately, researchers have conducted a number of clinical studies examining the role of stem cells in the treatment of inflammatory bowel disease. The most promising results have come from allogeneic mesenchymal stem cell therapy using stem cells derived from the umbilical cord. Research has found that allogeneic mesenchymal stem cells injected into a vein were able to induce a clinical response 3 out of 9 patients tested. One patient had complete clinical remission. In all cases, the stem cells increased the quality of life for patients. Five out of seven patients with inflammatory bowel disease had clinical remission after stem cell treatment. Likewise, further research showed that the stem cells could induce a clinical response and 12 of 15 patients and full clinical remission in eight of them. Here too, patients reported improved quality of life with stem cell treatment.
These results are incredibly promising and offer hope to patients struggling with ulcerative colitis and Crohn’s disease. While more research is needed, patients with inflammatory bowel disease should follow this field closely for new developments.
St. Petersburg, Florida
